Abstract:ABSTRACT The therapeutic potential of gene editing technologies hinges on the development of safe and effective delivery methods. In this study, we developed a temperature-sensitive and less immunogenic Sendai virus (ts SeV) as a novel delivery vector for CRISPR-Cas9 and for efficient gene editing in sensitive human cell types with limited induction of an innate immune response. ts SeV demonstrates high transduction efficiency in human CD34 + hematopoietic stem and progenitor cells (HSPCs) including transduction of the CD34 + /CD38 − /CD45RA − /CD90 + (Thy1 + )/CD49f high stem cell enriched subpopulation. The frequency of CCR5 editing exceeded 90% and bi-allelic CCR5 editing exceeded 70% resulting in significant inhibition of HIV-1 infection in primary human CD14 + monocytes. These results demonstrate the potential of the ts SeV platform as a safe, efficient, and flexible addition to the current gene-editing tool delivery methods, which may help further expand the possibilities in personalized medicine and the treatment of genetic disorders. IMPORTANCE Gene editing has the potential to be a powerful tool for the treatment of human diseases including HIV, β-thalassemias, and sickle cell disease. Recent advances have begun to overcome one of the major limiting factors of this technology, namely delivery of the CRISPR-Cas9 gene editing machinery, by utilizing viral vectors. However, gene editing therapies have yet to be implemented due to inherent risks associated with the DNA viral vectors typically used for delivery. As an alternative strategy, we have developed an RNA-based Sendai virus CRISPR-Cas9 delivery vector that does not integrate into the genome, is temperature sensitive, and does not induce a significant host interferon response. This recombinant SeV successfully delivered CRISPR-Cas9 in primary human CD14+ monocytes ex vivo resulting in a high level of CCR5 editing and inhibition of HIV infection.

Engineering single-cycle MeV vector for CRISPR-Cas9 gene editing

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Viral delivery of compact CRISPR-Cas12f for gene editing applications

A temperature-sensitive and interferon-silent Sendai virus vector for CRISPR-Cas9 delivery and gene editing in primary human cells

A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing

Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector

Efficient Genome Editing Achieved via Plug-and-Play Adenovirus Piggyback Transport of Cas9/gRNA Complex on Viral Capsid Surface

Rationally designed Campylobacter jejuni Cas9 enables efficient gene activation and base editing

Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies

Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo

Expression of Single mRNA Constructs Encoding Both CRISPR-Cas9 Protein and Guide RNAs for Future Gene Therapy Applications

Efficient Genome Editing Using 'NanoMEDIC' AsCas12a-VLPs Produced with Pol II-Transcribed crRNA

Computationally guided high-throughput engineering of an anti-CRISPR protein for precise genome editing in human cells

Gene editing by ferrying of CRISPR/Cas ribonucleoprotein complexes in enveloped virus-derived particles

Efficient Mutagenesis of Marek’s Disease Virus-Encoded microRNAs Using a CRISPR/Cas9-Based Gene Editing System

Programmed genome editing by a miniature CRISPR-Cas12f nuclease

Engineered Cas9 extracellular vesicles as a novel gene editing tool

Engineering Human ARMMs as Therapeutic Non-Viral Vehicles for in vivo Delivery of Genome Editing Payloads

Short term but highly efficient Cas9 expression mediated by excisional system using adenovirus vector and Cre

CRISPR/Cas9-AAV Mediated Knock-in at NRL Locus in Human Embryonic Stem Cells